New this year to the discussion at DIA is the conversation around data ownership, as the industry continues to face a deluge of information from more sources than ever.
Zenith-Cognizant Technologies emerges from an acquisition aimed to streamline solutions as more complex “smart factories” become a greater focus in the biopharmaceutical industry.
Two US Attorney Generals have opened an investigation into the data breach at AMCA that compromised a combined nearly 20 million patients at LabCorp and Quest Diagnostics – as the companies’ efforts to notify the public are called into question.
Iqvia leads the real world evidence market, which is at an inflection point, as pharma furthers its investment and vendors improve capabilities, according to a recent report.
Dassault Systèmes is set to acquire Medidata in an all-cash transaction valued at $5.8bn – a deal which will combine the power of modeling and simulation with data science to “catalyze the next generation of patient-inclusive therapeutics,” says CEO.
As regulators work to advance the modern clinical trial, the risk-averse clinical research industry is falling behind in the race to bring new therapies to patients, says an industry expert, echoing the former FDA commissioner’s calls for innovation.
Competitive costs, improving infrastructure, and a high burden of disease are increasing the demand for clinical research in Africa, says CRO, which has partnered with a US-based firm to expand its service offerings.
LabCorp and Quest Diagnostics this week disclosed unauthorized activity on the web payment page of the companies’ billing collections service provider.
The global oncology market last year set several records, though the industry continues to struggle with long development timelines, which in 2018 averaged 10.5 years from patent filing to regulatory approval and launch, according to a recent Iqvia report.
Broader clinical trial eligibility criteria would double patient numbers in lung cancer studies, according to a new report from ASCO, which has been leading efforts to expand access to oncology clinical trials.
This month’s roundup includes the first CFO for CytoReason, a new CEO at Certara and Factory-CRO, as well as an expanded leadership team at BioDuro, among other people on the move in May.
Risk-based monitoring should be described as a “best practice,” says ACRO, which recently released a survey that found the majority of new trial starts in 2018 employed some form of RBM.
Last year saw heightened market volatility, marked by international trade disputes, regulatory unrest, and a general feeling of uncertainty – but 2019 is off to a strong start with several multi-billion dollar deals.
Vetter’s German sites will be supplied with only CO2 neutral energy from renewable energy sources as the company continues to work towards greater sustainability.
